Janux Therapeutics, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.3M | $3.7M | $0 | $10.0M | $0 | $0 | $0 | $439.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $31.0M | $26.8M | $31.5M | $34.6M | $34.7M | $25.1M | $20.8M | $18.6M |
| SG&A Expense | $11.0M | $11.1M | $10.9M | $10.6M | $10.5M | $9.8M | $8.2M | $17.7M |
| Operating Income | $-31.7M | $-34.2M | $-42.4M | $-35.3M | $-45.1M | $-34.9M | $-29.0M | $-35.8M |
| Operating Margin | -308.7% | -916.5% | — | -352.5% | — | — | — | -8,164.5% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-22.0M | $-24.4M | $-31.9M | $-24.3M | $-33.9M | $-23.5M | $-20.2M | $-28.1M |
| Net Margin | -214.0% | -652.6% | — | -243.1% | — | — | — | -6,391.6% |
| EPS (Basic) | $-0.35 | $-0.39 | $-0.51 | $-0.39 | $-0.55 | $-0.38 | $-0.36 | $-0.51 |
| EPS (Diluted) | $-0.35 | $-0.39 | $-0.51 | $-0.39 | $-0.55 | $-0.38 | $-0.36 | $-0.51 |
| Shares Outstanding (Basic) | 62.9M | 62.7M | 62.0M | 62.0M | 61.9M | 61.8M | 53.8M | 54.6M |
| Shares Outstanding (Diluted) | 62.9M | 62.7M | 62.0M | 62.0M | 61.9M | 61.8M | 53.8M | 54.6M |
| Dividends Per Share | — | — | — | — | — | — | — | — |